Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease PatientsGlobeNewsWire • 06/12/24
Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)PRNewsWire • 06/10/24
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business UpdatesGlobeNewsWire • 05/15/24
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's DiseaseGlobeNewsWire • 04/11/24
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual MeetingGlobeNewsWire • 04/03/24
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International ConferenceGlobeNewsWire • 03/08/24
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 02/28/24
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business UpdatesGlobeNewsWire • 02/22/24
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)GlobeNewsWire • 02/08/24
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 01/03/24
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy BodiesGlobeNewsWire • 12/12/23
Athira Pharma to Participate in Sidoti December Small Cap Investor ConferenceGlobeNewsWire • 11/29/23
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's DiseaseGlobeNewsWire • 11/15/23
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)GlobeNewsWire • 10/05/23
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/19/23
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to BuyZacks Investment Research • 09/08/23
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)Zacks Investment Research • 08/31/23